塞替派在血液淋巴系统肿瘤和造血干细胞移植中临床应用的中国专家共识(2024年版)  

Chinese expert consensus on the clinical application of thiotepa in hematological and lymphatic system tumors and hematopoietic stem cell transplantation(2024 version)

作　　者：中国临床肿瘤学会(CSCO)白血病专家委员会 中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 赵东陆[2] 王志国[2] 王小沛 刘卫平 马军[2] Leukemia Expert Committee of Chinese Society of Clinical Oncology(CSCO);Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun(不详;Harbin Institute of Hematology and Oncology,Harbin 150010,China)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010 [3]北京大学肿瘤医院

出　　处：《白血病．淋巴瘤》2024年第10期587-595,共9页Journal of Leukemia & Lymphoma

摘　　要：塞替派是一种烷化剂,具有很好的透过血脑屏障的能力,目前已被用于治疗多种淋巴造血系统疾病及造血干细胞移植预处理,其在中枢神经系统淋巴瘤的诱导化疗及中枢神经系统侵犯的预防和治疗方面也显示出良好的临床效果。专家组参考国内外相关研究结果等循证医学证据,讨论形成塞替派在血液淋巴系统肿瘤和造血干细胞移植中临床应用的中国专家共识,以更好地指导临床医师规范合理用药。Thiotepa is an alkylating agent with good ability to cross the blood-brain barrier and has been widely used in the treatment of a variety of lymphohematopoietic diseases and pretreatment for hematopoietic stem cell transplantation.Thiotepa also shows a promising clinical outcome for induction chemotherapy of central nervous system(CNS)lymphoma and prevention and treatment of CNS invasion.Based on evidence-based medicine evidences including reports from the relevant domestic and foreign literatures,the expert group proposed recommendations and formed this consensus to better guide clinicians to standardize and rationalize application of thiotepa.

关 键 词：塞替派 造血干细胞移植 移植预处理 重型Β地中海贫血 急性白血病 中枢神经系统淋巴瘤 

分 类 号：R457.7[医药卫生—治疗学] R733[医药卫生—临床医学]